Harry Miller Corp. v. Mancuso Chemicals Limited

468 F. Supp. 2d 708, 2006 U.S. Dist. LEXIS 93082, 2006 WL 3825154
CourtDistrict Court, E.D. Pennsylvania
DecidedDecember 22, 2006
Docket99-CV-2669
StatusPublished
Cited by1 cases

This text of 468 F. Supp. 2d 708 (Harry Miller Corp. v. Mancuso Chemicals Limited) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Harry Miller Corp. v. Mancuso Chemicals Limited, 468 F. Supp. 2d 708, 2006 U.S. Dist. LEXIS 93082, 2006 WL 3825154 (E.D. Pa. 2006).

Opinion

MEMORANDUM AND ORDER

ANITA B. BRODY, District Judge.

I. Introduction

Plaintiff Harry Miller Corp. (“Miller”) brings against defendant Mancuso Chemi *710 cals Limited (“Mancuso”) an action for violation of the Racketeering Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. § 1961, et. seq., among their claims. Defendant chose to file seven separate summary judgment motions. This memorandum will address the summary judgment motion relating to the RICO claims, Counts II and III of the Amended Complaint. The motion will be granted.

II. Jurisdiction

Subject matter jurisdiction exists to consider plaintiffs RICO claims under 28 U.S.C. § 1331.

III. Background 1

Miller is a chemical company that produces a number of products, including a hydrochloric acid inhibitor known as Acti-vol 1803 (“Activol”). A hydrochloric acid inhibitor removes “scale” that accrues on steel as the steel oxidizes, while simultaneously protecting the steel from further corrosion. The formula for Activol is Miller’s trade secret. 2 In November 1990, Paul Carr, then an employee of Miller, incorporated his own chemical company, “Carr Chem.” In December 1990, Carr left Miller’s employ with Miller’s formula for Activol 1803 in hand. Carr began selling a product identical to Activol 1803 under the trade name “Can-Hib.” Carr sold Can-Hib to customers such as Dofasco, a large Canadian steel company. Dofasco had previously bought Activol from Miller and had ceased doing so around the same time that it began purchasing Can-Hib from Carr Chem.

In 1997, Miller sued Carr and Carr Chem for misappropriation of its trade secret. Harry Miller Corporation v. Paul Carr and Carr Chem, Inc. (under seal) (“the Carr Litigation”). The Carr Litigation settled in 1999 with Carr assigning to Miller all of its rights in Can-Hib. During the course of the Carr Litigation, Miller believed it had discovered for the first time that Carr had communicated the formula for Activol to Mancuso, the defendant in this litigation, and that Mancuso was, in fact, the true manufacturer of Can-Hib.

In 1999, Miller brought this action against Mancuso, alleging a number of state law claims and violation of the RICO statute, 18 U.S.C. § 1962(c)-(d). Miller’s RICO claims arise out of Carr’s and Man-cuso’s conduct during the Carr Litigation and supposedly after the settlement of that case. During the Carr Litigation, Carr and Mancuso denied that Can-Hib utilized the same formula as Activol. Instead, they contended that at a meeting on January 3, 1991, a man named Gary Young, now deceased, threw a formula across a table to Mancuso. Mancuso maintained that this formula was for an acid inhibitor, that Young’s formula was unworkable, and that Mancuso’s chemist refined it and turned it into a viable product. This refined product was sold as “Can-Hib.” In this present action, Miller contends that this so-called “Gary Young alibi” is false and that Mancuso committed the predicate RICO acts of obstruction of justice, mail fraud and wire fraud during and after the Carr Litigation. Miller claims that Man-cuso committed these acts during the Carr Litigation by conspiring with Carr and asserting the Gary Young alibi in declarations and deposition testimony in that case. Miller also accuses Mancuso of continuing *711 to commit predicate acts of racketeering by using the mails and wires to sell an acid inhibitor based on the misappropriated Ac-tivol formula and by continuing to assert the Gary Young alibi in this action.

After combing all of Miller’s meandering submissions in support of its RICO claims, I have determined that the only facts that Miller presents arguably relevant to its RICO claims are the following:

• During the Carr Litigation, Paul Carr filed two false declarations. In Carr’s first declaration, dated January 8, 1998, Carr denied that he misappropriated plaintiffs trade secret. Carr asserted that his company, Carr-Chem, had developed its own inhibitors with the assistance of outside blenders. Plaintiffs Ex. 83. 3
• In Carr’s second declaration, dated January 15, 1998, Carr again denied that he had stolen plaintiffs formula for Activol. He denied that his product, Can-Hib, was identical to Activol. Plaintiffs Ex. 34. Carr declared that he had purchased the original acid inhibitor formula from a man named Gary Young, but that Carr Chem had also refined, reformulated and experimented with that formula. M 4
• At his deposition in the Carr Litigation, 5 Carr testified that Carr Chem never owned a formula for an acid inhibitor. Plaintiffs Ex. 1 at 36:6-23, 37:1.
• Carr also testified that Mancuso owned the formula for Can-Hib 1991 because “they [Mancuso] took a formulation given to them by Mr. Gary Young and developed that to a formula that was workable.” Id. at 41:1-10.
• Carr denied that he and Mancuso ever ' entered into a formal contract and insisted that a “gentlemen’s agreement” governed their dealings. Id. at 57:2-13.
• During discovery in the Carr litigation, Mancuso produced a purported confidentiality agreement between Carr and Mancuso, signed by Mancuso’s general manager John Henstock, and dated December 28, 1990. Plaintiffs Ex. 20. The agreement imposes on Mancuso the following obligations: -Mancuso will keep confidential all “information, drawings, specifications, data, know-how and all other communication, oral or written,” disclosed or provided to Mancuso by Carr Chem, Inc. regarding Carr Chem, Inc. (“Information”).
-Mancuso will not use any Information other than for the purpose of blending and/or reacting CAN-HIB-1991 and other formulations marked “confidential.”
-Mancuso’s officers and employees are similarly bound to maintain the confidentiality of Information communicated to them.
-All tangible Information shall remain the property of Carr Chem, Inc.
• During the course of the Carr Litigation, employees of Mancuso filed sworn declarations attesting that they *712 had personal information relevant to the litigation, and that the substance of each of their testimony was “explained more fully in the Declaration of Paul Carr.... ” Plaintiffs Ex. 35-37. Each declaration was transmitted by facsimile from Paul Carr’s attorney in Buffalo, New York to each declar-ant. Plaintiffs Ex. 97.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lester v. Percudani
556 F. Supp. 2d 473 (M.D. Pennsylvania, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
468 F. Supp. 2d 708, 2006 U.S. Dist. LEXIS 93082, 2006 WL 3825154, Counsel Stack Legal Research, https://law.counselstack.com/opinion/harry-miller-corp-v-mancuso-chemicals-limited-paed-2006.